Agios Pharmaceuticals Inc (NASDAQ: AGIO) kicked off on Friday, up 3.49% from the previous trading day, before settling in for the closing price of $34.34. Over the past 52 weeks, AGIO has traded in a range of $27.14-$62.58.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 4.89%. While this was happening, its average annual earnings per share was recorded -162.31%. With a float of $55.21 million, this company’s outstanding shares have now reached $57.16 million.
Considering the fact that the conglomerate employs 488 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 80.53%, operating margin of -1166.47%, and the pretax margin is 1967.15%.
Agios Pharmaceuticals Inc (AGIO) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Agios Pharmaceuticals Inc is 3.64%, while institutional ownership is 106.81%. The most recent insider transaction that took place on Feb 05 ’25, was worth 78,134. In this transaction Principal Accounting Officer of this company sold 2,272 shares at a rate of $34.39, taking the stock ownership to the 5,437 shares. Before that another transaction happened on Jan 06 ’25, when Company’s Chief Commercial Officer sold 2,804 for $32.18, making the entire transaction worth $90,233. This insider now owns 18,906 shares in total.
Agios Pharmaceuticals Inc (AGIO) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.85 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -162.31% per share during the next fiscal year.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) Trading Performance Indicators
Take a look at Agios Pharmaceuticals Inc’s (AGIO) current performance indicators. Last quarter, stock had a quick ratio of 11.56. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 55.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 11.40, a number that is poised to hit -1.73 in the next quarter and is forecasted to reach -6.13 in one year’s time.
Technical Analysis of Agios Pharmaceuticals Inc (AGIO)
Compared to the last year’s volume of 0.76 million, its volume of 0.8 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 60.88%. Additionally, its Average True Range was 1.55.
During the past 100 days, Agios Pharmaceuticals Inc’s (AGIO) raw stochastic average was set at 13.32%, which indicates a significant decrease from 86.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 31.89% in the past 14 days, which was lower than the 64.63% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $34.42, while its 200-day Moving Average is $42.93. Nevertheless, the first resistance level for the watch stands at $36.04 in the near term. At $36.53, the stock is likely to face the second major resistance level. The third major resistance level sits at $37.53. If the price goes on to break the first support level at $34.55, it is likely to go to the next support level at $33.55. Now, if the price goes above the second support level, the third support stands at $33.06.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) Key Stats
The company with the Market Capitalisation of 2.04 billion has total of 57,296K Shares Outstanding. Its annual sales at the moment are 36,500 K in contrast with the sum of 673,730 K annual income. Company’s last quarter sales were recorded 10,730 K and last quarter income was -96,520 K.
